Setting up a wide panel of patient-derived tumor xenografts of non-small cell lung cancer by improving the preanalytical steps

Cancer Medicine

Volumn 4, Issue 2, 2015, Pages 201-211

  Ilie, Marius ^a,b,c   Nunes, Manoel ^d   Blot, Lydia ^d   Hofman, Véronique ^a,b,c   Long Mira, Elodie ^a,b,c   Butori, Catherine ^a,b   Selva, Eric ^a   Merino Trigo, Ana ^d   Vénissac, Nicolas ^a,b,c   Mouroux, Jérôme ^a,b,c   Vrignaud, Patricia ^d   Hofman, Paul ^a,b,c  

^a PASTEUR HOSPITAL   (France)

^b UNIVERSITY OF NICE SOPHIA ANTIPOLIS   (France)

^c UNIVERSITÉ CÔTE D'AZUR   (France)

^d SANOFI   (France)

Author keywords

Molecular pathology; NSCLC; PDX; Preanalytical

Indexed keywords

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAF GENE; CANCER MODEL; CANCER PATIENT; CONTROLLED STUDY; DISEASE FREE SURVIVAL; EGFR GENE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; MALE; MEK1 GENE; MOUSE; NEXT GENERATION SEQUENCING; NON SMALL CELL LUNG CANCER; NONHUMAN; ONCOGENE; ONCOGENE K RAS; ONCOGENE N RAS; PI3KCA GENE; PRIORITY JOURNAL; PTEN GENE; SQUAMOUS CELL LUNG CARCINOMA; TUMOR XENOGRAFT; ANIMAL; CANCER TRANSPLANTATION; DISEASE MODEL; DNA SEQUENCE; GENETICS; LUNG TUMOR; MIDDLE AGED; NUDE MOUSE; PATHOLOGY; SCID MOUSE; SURVIVAL; VERY ELDERLY; XENOGRAFT;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE MODELS, ANIMAL; FEMALE; HETEROGRAFTS; HUMANS; LUNG NEOPLASMS; MALE; MICE; MICE, NUDE; MICE, SCID; MIDDLE AGED; NEOPLASM TRANSPLANTATION; SEQUENCE ANALYSIS, DNA; SURVIVAL ANALYSIS;

EID: 84964694710     PISSN: None     EISSN: 20457634     Source Type: Journal    
DOI: 10.1002/cam4.357     Document Type: Article

References (31)

1. Siegel, R., D. Naishadham, and A. Jemal . 2013. Cancer statistics, 2013. CA Cancer J. Clin. 63:11-30.
2. Lazar, V., C. Suo, C. Orear, J. van den Oord, Z. Balogh, J. Guegan, et al. 2013. Integrated molecular portrait of non-small cell lung cancers. BMC Med. Genomics 6:53.
3. Bedard, P. L., A. R. Hansen, M. J. Ratain, and L. L. Siu . 2013. Tumour heterogeneity in the clinic. Nature 501:355-364.
4. Fichtner, I., J. Rolff, R. Soong, J. Hoffmann, S. Hammer, A. Sommer, et al. 2008. Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers. Clin. Cancer Res. 14:6456-6468.
5. Merk, J., J. Rolff, M. Becker, G. Leschber, and I. Fichtner . 2009. Patient-derived xenografts of non-small-cell lung cancer: a pre-clinical model to evaluate adjuvant chemotherapy? Eur. J. Cardiothorac. Surg. 36:454-459.
6. Zhang, X. C., J. Zhang, M. Li, X. S. Huang, X. N. Yang, W. Z. Zhong, et al. 2013. Establishment of patient-derived non-small cell lung cancer xenograft models with genetic aberrations within EGFR, KRAS and FGFR1: useful tools for preclinical studies of targeted therapies. J. Transl. Med. 11:168.
7. John, T., D. Kohler, M. Pintilie, N. Yanagawa, N. A. Pham, M. Li, et al. 2011. The ability to form primary tumor xenografts is predictive of increased risk of disease recurrence in early-stage non-small cell lung cancer. Clin. Cancer Res. 17:134-141.
8. Moro, M., G. Bertolini, M. Tortoreto, U. Pastorino, G. Sozzi, and L. Roz . 2012. Patient-derived xenografts of non small cell lung cancer: resurgence of an old model for investigation of modern concepts of tailored therapy and cancer stem cells. J. Biomed. Biotechnol. 2012:568567.
9. Bertolini, G., L. Roz, P. Perego, M. Tortoreto, E. Fontanella, L. Gatti, et al. 2009. Highly tumorigenic lung cancer CD133 + cells display stem-like features and are spared by cisplatin treatment. Proc. Natl. Acad. Sci. USA 106:16281-16286.
10. Hammer, S., A. Sommer, I. Fichtner, M. Becker, J. Rolff, J. Merk, et al. 2010. Comparative profiling of the novel epothilone, sagopilone, in xenografts derived from primary non-small cell lung cancer. Clin. Cancer Res. 16:1452-1465.
11. Tentler, J. J., A. C. Tan, C. D. Weekes, A. Jimeno, S. Leong, T. M. Pitts, et al. 2012. Patient-derived tumour xenografts as models for oncology drug development. Nat. Rev. Clin. Oncol. 9:338-350.
12. Hofman, P. and C Lagardère . 2011. French biobank secures specimens. RFID J. Available at: http://www.rfidjournal.com/article/view/8303 (accessed 24 April 2014).
13. Kubo, T., H. Yamamoto, W. W. Lockwood, I. Valencia, J. Soh, M. Peyton, et al. 2009. MET gene amplification or EGFR mutation activate MET in lung cancers untreated with EGFR tyrosine kinase inhibitors. Int. J. Cancer 124:1778-1784.
14. Schildhaus, H. U., L. C. Heukamp, S. Merkelbach-Bruse, K. Riesner, K. Schmitz, E. Binot, et al. 2012. Definition of a fluorescence in-situ hybridization score identifies high- and low-level FGFR1 amplification types in squamous cell lung cancer. Mod. Pathol. 25:1473-1480.
15. Karolchik, D., R. Baertsch, M. Diekhans, T. S. Furey, A. Hinrichs, Y. T. Lu, et al. 2003. The UCSC Genome Browser Database. Nucleic Acids Res. 31:51-54.
16. Cancer Genome Atlas Research N. 2012. Comprehensive genomic characterization of squamous cell lung cancers. Nature 489:519-525.
17. Imielinski, M., A. H. Berger, P. S. Hammerman, B. Hernandez, T. J. Pugh, E. Hodis, et al. 2012. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell 150:1107-1120.
18. Riely, G. J., J. Marks, and W. Pao . 2009. KRAS mutations in non-small cell lung cancer. Proc. Am. Thorac. Soc. 6:201-205.
19. Justilien, V., A. P. Fields . 2013. Utility and applications of orthotopic models of human non-small cell lung cancer (NSCLC) for the evaluation of novel and emerging cancer therapeutics. Curr. Protoc. Pharmacol. 62:Unit 14. 27.
20. Yamazaki, S., P. Vicini, Z. Shen, H. Y. Zou, J. Lee, Q. Li, et al. 2012. Pharmacokinetic/pharmacodynamic modeling of crizotinib for anaplastic lymphoma kinase inhibition and antitumor efficacy in human tumor xenograft mouse models. J. Pharmacol. Exp. Ther. 340:549-557.
21. Christensen, J. G. 2011. Proof of principle for crizotinib in anaplastic lymphoma kinase-positive malignancies was achieved in ALK-positive nonclinical models. Mol. Cancer Ther. 10:2024.
22. Yoshida, T., I. Okamoto, W. Okamoto, E. Hatashita, Y. Yamada, K. Kuwata, et al. 2010. Effects of Src inhibitors on cell growth and epidermal growth factor receptor and MET signaling in gefitinib-resistant non-small cell lung cancer cells with acquired MET amplification. Cancer Sci. 101:167-172.
23. Dong, X., J. Guan, J. C. English, J. Flint, J. Yee, K. Evans, et al. 2010. Patient-derived first generation xenografts of non-small cell lung cancers: promising tools for predicting drug responses for personalized chemotherapy. Clin. Cancer Res. 16:1442-1451.
24. Nemati, F., R. Bras-Goncalves, J. J. Fontaine, G. de Pinieux, P. De Cremoux, A. Chapelier, et al. 2009. Preclinical assessment of cisplatin-based therapy versus docetaxel-based therapy on a panel of human non-small-cell lung cancer xenografts. Anticancer Drugs 20:932-940.
25. Chen, K., S. Ahmed, O. Adeyi, J. E. Dick, and A. Ghanekar . 2012. Human solid tumor xenografts in immunodeficient mice are vulnerable to lymphomagenesis associated with Epstein-Barr virus. PLoS One 7:e39294.
26. Ding, L., M. J. Ellis, S. Li, D. E. Larson, K. Chen, J. W. Wallis, et al. 2010. Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature 464:999-1005.
27. Travis, W. D., E. Brambilla, H. K. Müller-Hermelink, and C. C. Harris . 2004. WHO histological classification of tumors of the lung. World Health Organization Classification of Tumours Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. IARC Press, Lyon, France.
28. Malaney, P., S. V. Nicosia, and V. Dave . 2014. One mouse, one patient paradigm: new avatars of personalized cancer therapy. Cancer Lett. 344:1-12.
29. Mattie, M., A. Christensen, M. S. Chang, W. Yeh, S. Said, Y. Shostak, et al. 2013. Molecular characterization of patient-derived human pancreatic tumor xenograft models for preclinical and translational development of cancer therapeutics. Neoplasia 15:1138-1150.
30. Zhang, X., S. Claerhout, A. Prat, L. E. Dobrolecki, I. Petrovic, Q. Lai, et al. 2013. A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models. Cancer Res. 73:4885-4897.
31. Julien, S., A. Merino-Trigo, L. Lacroix, M. Pocard, D. Goere, P. Mariani, et al. 2012. Characterization of a large panel of patient-derived tumor xenografts representing the clinical heterogeneity of human colorectal cancer. Clin. Cancer Res. 18:5314-5328.